Motif Bio PLC Motif Bio to present at BIO-Europe Spring
23 Marzo 2016 - 8:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
23 March 2016
Motif Bio plc
("Motif" or the "Company")
Motif Bio to present at BIO-Europe Spring
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that the Company has been selected to present at the 10(th)
International Partnering Conference, BIO-Europe Spring(R) taking
place at the Kistamässan Convention Center in Stockholm, Sweden
over April 4-6.
The presentation will be given by Dr. Graham Lumsden, CEO of
Motif Bio and will take place in Room E6/7 (level 0) on Tuesday,
April 5 2016 at 14:15 CET.
BIO-Europe Spring(R) is the springtime counterpart to EBD
Group's flagship conference, BIO-Europe(R) and continues the
tradition of providing life science companies with high calibre
partnering opportunities. The conference annually attracts an
international "who's who" from biotech, pharma, and finance for
three days networking and meetings.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
David Huang (Chief Medical Officer)
Zeus Capital Limited (NOMAD &
BROKER)
Phil Walker/Dan Bate
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners Limited
(BROKER)
Patrick Claridge/ David Hignell
John Howes/ Rob Rees (Broking) +44 (0)203 861 6625
Walbrook PR Ltd. (FINANCIAL PR +44 (0) 20 7933 8780 or motifbio@walbrookpr.com
& IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio (www.motifbio.com)
Motif is a clinical-stage biopharmaceutical company,
specialising in the development of novel antibiotics that are
designed to be effective against serious and life-threatening
infections caused by multi-drug resistant bacteria. Our lead
product candidate, iclaprim, is being developed for the treatment
of the most common and serious bacterial infections such as acute
bacterial skin and skin structure infections (ABSSSI) and hospital
acquired bacterial pneumonia (HABP), including those caused by
resistant strains such as MRSA (methicillin-resistant
Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on
track to be completed in 2017 and if approved, iclaprim could be
ready for commercialization in 2018. The Company is in discussions
with pharmaceutical companies and universities to build a pipeline
of innovative antibiotics targeting Gram-positive and Gram-negative
bacteria.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFITVIIFFIR
(END) Dow Jones Newswires
March 23, 2016 03:01 ET (07:01 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024